Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single-cell transcriptomes of subcutaneous and orthotopic RM-1 mouse prostate tumors collected 7 days after sham or irreversible electroporation

ABSTRACT: This submission describes a single-cell RNA-sequencing resource generated from two mouse prostate cancer models. The dataset contains six subcutaneous RM-1 tumors and four orthotopic RM-1 prostate tumors collected 7 days after sham intervention or irreversible electroporation (IRE). Each excised tumor represents one biological replicate and was processed as an independent whole-cell suspension before library construction. Raw sequencing reads were previously submitted to SRA under BioProject PRJNA1497318 and are linked here through the corresponding SRA accessions. The GEO submission provides the processed filtered gene-barcode matrices used for downstream quality control, integration, clustering, and cell-type annotation.

ORGANISM(S): Mus musculus

PROVIDER: GSE341190 | GEO | 2026/08/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Single-cell transcriptomes of paired peripheral blood mononuclear cells collected before and 7 days after irreversible electroporation in patients with localized prostate cancer

Project description:This submission describes paired single-cell RNA-sequencing profiles of peripheral blood mononuclear cells (PBMCs) from five patients with clinically localized prostate cancer undergoing irreversible electroporation (IRE). For each participant, one PBMC sample was collected immediately before IRE and one PBMC sample was collected 7 days after IRE, generating ten independent single-cell libraries. Raw sequencing reads were previously submitted to SRA under BioProject PRJNA1497318 and are linked here through the corresponding SRA accessions. The GEO submission provides the processed filtered gene-barcode matrices used for downstream quality control, integration, clustering, and annotation.

2026-08-01 | GSE341191 | GEO

Targeting Tumor-associated CCR2+ Macrophages with Proteolipid Nanovesicles to Inhibit Pancreatic Cancer Recurrence Following Irreversible Electroporation

Project description:Irreversible electroporation (IRE) has emerged as a promising radical ablative therapy for PDAC; however, its clinical efficacy is hindered by the high recurrence rate. Herein, using a preclinical orthotopic PDAC tumor model, we comprehensively characterized the tumor immune microenvironment following IRE treatment through scRNA-seq. Our findings provide direct evidence that IRE treatment induces a CCR2+ tumor-associated macrophages (CCR2+ TAMs)-mediated immunosuppressive microenvironment in the residual tumor, ultimately accelerating tumor recurrence. Targeting CCR2+ TAMs enhances antitumor immunity and improves the chemotherapeutic response in PDAC.

2026-01-01 | GSE292490 | GEO

Irreversible Electroporation of Unresectable Liver Tumors

Project description:The aim of this study is to evaluate the safety and feasibility of curative intended irreversible electroporation (IRE) in the treatment of liver tumors neighboring major vessels or bile ducts.

| 2340479 | ecrin-mdr-crc

Deinococcus sp. RM strain:RM

Project description:Deinococcus sp. RM strain:RM Genome sequencing and assembly

| PRJNA489992 | ENA

Rhizobium sp. RM strain:RM

Project description:Rhizobium sp. RM strain:RM Genome sequencing and assembly

| PRJNA641501 | ENA

Irreversible Electroporation (NanoKnife ) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer

Project description:The goal of this pilot clinical trial is to learn about the combination of immune boosting drugs and irreversible electroporation (IRE) in patients with colon cancer that has spread to the liver (metastasis). The main questions it aims to answer are: 1. to document the rate of complications associated with combining IRE with immune boosting drugs. 2. After one liver metastasis is treated with IRE and immune boosting drugs, what is the change in the size of the non-IRE-treated liver metastases? 3. What is the immune response (measured in a blood sample) when IRE is combined with one or two types of immune boosting drugs?

| 92707 | ecrin-mdr-crc

Efficacy of Irreversible Electroporation (IRE) for Central Colorectal Liver Metastases

Project description:Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels and bile ducts. With IRE, multiple electrical pulses are applied to tumorous tissue. These pulses alter the existing transmembrane potential of the cell membranes, and create ‘nanopores’, after which the cell dies through loss of homeastasis. The purpose of this study is to investigate the efficacy of percutaneous and open IRE in the treatment of patients with colorectal liver metastases (CRLM) that are unsuitable for resection or thermal ablation due to vicinity to vulnerable structures such as vessels and bile ducts. Other objectives are safety, feasibility (technical success) and imaging characteristics on follow-up (PET-)CT and PET-MRI and the value of these imaging modalities in dianosing local site recurrence (LSR) or residual disease (RD). 29 patients with histologically confirmed colorectal carcinoma who present with unresectable and not thermally ablative CRLM< 3.5cm suitable for IRE will undergo percutaneous or open irreversible electroporation of the tumor using CT and ultrasound guidance. All (serious) adverse events are registered. One day post-IRE MRI is performed to assess technical success. Follow-up will consist of frequent (PET-)CT and (PET-)MRI scanning to localize residual or recurrent disease. Overall technique effectiveness is determined 1 year after treatment. The investigators hypothesize that IRE for central CRLM will lead to good tumor control without causing severe complications.

| 2162342 | ecrin-mdr-crc

Transcriptomic analysis of Dunaliella salina cultivated in Sistan deep water

Project description:RNA sequencing was performed to investigate the transcriptomic response of Dunaliella salina cultivated in Sistan deep water. Four RNA-seq libraries representing two biological replicates for the control and two biological replicates for the deep water treatment were generated using the Illumina NovaSeq 6000 platform. Raw sequencing data are available in SRA under BioProject PRJNA1267574. Processed gene count data are provided.

2026-07-21 | GSE339343 | GEO

Evolution of Translation Regulation in budding Yeast

Project description:Comparison of translation efficiency in S. cerevisiae, S. paradoxus, and their F1 hybrid. SRA submission number SRP028552; BioProject number PRJNA213844; Ribosome profiling was used to compare mRNA abundance, ribosome occupancy, and translation efficiency in two yeast species and their F1 hybrid.

2013-12-04 | E-GEOD-52119 | biostudies-arrayexpress

Pilot-study: Non-thermal Ablation Using Irreversible Electroporation to Treat Colorectal Liver Metastases

Project description:Irreversible electroporation is a new, minimal-invasive image-guided treatment to treat tumors near or around vulnerable structures, such as central liver tumors. To investigate the safety and efficacy of IRE in the treatment of colorectal liver metastases, patients with resectable colorectal liver metastases undergo IRE and resection of the metastases in the same session. After resection, the specimen is examined macroscopically to determine vitality using a specific vitality staining (triphenyl-tetrazoliumchloride) and to visualize the exact ablation zone. Subsequently, histopathologic examination is used to determine type of cell death and the microscopic ablation zone. The investigators hypothesize that IRE is a safe effective method to treat colorectal liver metastasis and that cell damage and cell death is demonstrated as soon as 1 hour after the procedure.

| 2140639 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data